Deuterium

Cambridge Isotope Laboratories (CIL) Shows Long-Term Commitment to Xenia, Ohio, Facility With New Land Purchase

Retrieved on: 
Thursday, April 25, 2024

TEWKSBURY, MA, Apr 25, 2024 - (ACN Newswire) - Cambridge Isotope Laboratories, Inc. (CIL) has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) Xenia, Ohio location.

Key Points: 
  • TEWKSBURY, MA, Apr 25, 2024 - (ACN Newswire) - Cambridge Isotope Laboratories, Inc. (CIL) has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) Xenia, Ohio location.
  • Mike Steiger, Vice President of Engineering and Project Execution for CIL, stated that the new land purchase will ensure easier access to utilities for future expansion.
  • This newly acquired land is situated to the west of the 20 acres purchased in 2017, which is currently the site of the North Star expansion project.
  • North Star is the largest 13C separation facility ever built in the world and will significantly increase CIL's capacity ensuring customer reliability for this stable isotope.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 22, 2024

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $5.9 million as of December 31, 2023, compared with $12.1 million as of December 31, 2022.
  • In August 2023 Salarius announced a comprehensive review of strategic alternatives focused on maximizing shareholder value.
  • Research and development expenses were $0.06 million for the fourth quarter of 2023, compared with $4.7 million for the fourth quarter of 2022, reflecting the above-mentioned cost-savings plan.
  • Net cash used for operating activities during the fourth quarter of 2023 was $1.5 million, compared with $4.7 million during the same quarter in 2022, reflecting the above-mentioned cost-savings plan.

Stellarex, Inc. and Canadian Nuclear Laboratories Sign MOU to Collaborate on the Development of Fusion Energy

Retrieved on: 
Monday, March 18, 2024

Under the terms of the collaboration, Stellarex and CNL will partner in specific areas of fusion energy science and technology towards the design and realization of Stellarex’s planned fusion energy power plants.

Key Points: 
  • Under the terms of the collaboration, Stellarex and CNL will partner in specific areas of fusion energy science and technology towards the design and realization of Stellarex’s planned fusion energy power plants.
  • "Stellarex is delighted to be collaborating with Canadian Nuclear Laboratories,” said Professor Amitava Bhattacharjee, Co-Founder and Chief Science Officer of Stellarex, also of Princeton University.
  • "CNL has exceptional experience in many key areas of importance in developing our stellarator fusion energy devices."
  • “Canada is in the midst of rapidly growing our work in fusion energy technologies, and CNL is excited to partner with Stellarex in its pursuit of a magnetic fusion energy based on the stellarator approach,” said Dr. Stephen Bushby, Vice-President, Science and Technology, Canadian Nuclear Laboratories.

Rapid Novor and MAbSilico Partner for World's First AI-Guided Epitope Mapping Service for Antibodies

Retrieved on: 
Wednesday, March 13, 2024

KITCHENER, ON, March 13, 2024 /PRNewswire-PRWeb/ -- Rapid Novor Inc and MAbSilico announced that they have partnered to provide the world's first AI-driven HDX-MS epitope mapping service for antibody development. By seamlessly integrating experimental data from HDX-MS with predictive analytics derived from AI-driven computational modeling, researchers can gain a comprehensive understanding of antibody structure, dynamics, and interactions with unparalleled precision and speed.

Key Points: 
  • Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service.
  • KITCHENER, ON, March 13, 2024 /PRNewswire-PRWeb/ -- Rapid Novor Inc and MAbSilico announced that they have partnered to provide the world's first AI-driven HDX-MS epitope mapping service for antibody development.
  • "Artificial intelligence promises a turning point in antibody drug discovery and development," states Iain Rogers, VP Sales and Marketing at Rapid Novor.
  • "This AI-integrated approach enables rapid screening of antibodies from extensive candidate pools," adds Zak Omahdi, Scientific Business Developer at MAbSilico.

US Nuclear’s Overhoff Branch is Fusion Energy’s Go-To Tritium Monitoring Solution

Retrieved on: 
Tuesday, February 20, 2024

US Nuclear’s (OTC-QB: UCLE) Overhoff Technology branch is the go-to solution for tritium monitoring instrumentation, with over 50 years of experience manufacturing tritium monitoring products for the DOE, DOD, military, nuclear power plants, and industrial manufacturers.

Key Points: 
  • US Nuclear’s (OTC-QB: UCLE) Overhoff Technology branch is the go-to solution for tritium monitoring instrumentation, with over 50 years of experience manufacturing tritium monitoring products for the DOE, DOD, military, nuclear power plants, and industrial manufacturers.
  • In fact, Overhoff is now set to complete the shipment to a U.S. DOE facility totaling $421,500 for portable monitors used for measuring tritium in air.
  • Now, as fusion power ushers in a new, likely trillion-dollar industry, directly centered around tritium, Overhoff is poised to be the foremost provider for tritium monitoring equipment and is already working with several major fusion power projects.
  • Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Retrieved on: 
Tuesday, December 5, 2023

“In our study of CYB003 for MDD, we observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose.

Key Points: 
  • “In our study of CYB003 for MDD, we observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose.
  • “As evidenced in each of these presentations, our deuterated programs – psilocybin analog (CYB003) and DMT compounds (CYB004 and SPL028) – are producing highly encouraging results.
  • This is a transformational time for Cybin, with several upcoming value-driving catalysts as we advance our clinical programs.
  • Following on from our recently announced Phase 2 topline efficacy data for CYB003, we expect to have Phase 1 dosing, PK/PD, and safety data for CYB004 and intramuscular dosing data for SPL028 around year end 2023.

Focused Energy Partners with LLNL on a Target Design for Inertial Fusion Energy

Retrieved on: 
Tuesday, November 7, 2023

Focused Energy and Lawrence Livermore National Laboratory (LLNL) have signed a Strategic Partnership Project Agreement for LLNL to assist the American-German fusion company with developing and assessing the performance of isochoric compression target designs for inertial fusion energy.

Key Points: 
  • Focused Energy and Lawrence Livermore National Laboratory (LLNL) have signed a Strategic Partnership Project Agreement for LLNL to assist the American-German fusion company with developing and assessing the performance of isochoric compression target designs for inertial fusion energy.
  • At LLNL’s National Ignition Facility (NIF), inertial fusion ignition and target gain > 1 were achieved in December 2022 - a historic breakthrough for the future production of clean energy.
  • Under this contract, LLNL will use its codes and tools to help Focused Energy study and optimize target designs for achieving high compression in ischoric fuel assemblies required for fast ignition inertial confinement fusion.
  • “We are very pleased to have another renowned partner on board with LLNL to optimise the target design together”, said Thomas Forner, CEO and co-founder of Focused Energy.

US Nuclear’s Partner Develops Revolutionary Technology for Total Cleaning of Radioactive Wastewater

Retrieved on: 
Wednesday, November 1, 2023

Arbok-Nuclear is the only company in the world able to remove 100% of radioactive contamination from water.

Key Points: 
  • Arbok-Nuclear is the only company in the world able to remove 100% of radioactive contamination from water.
  • All due to the inability and failure of all other methods to completely clean the Fukushima water.
  • Arbok is set to redefine the way the world approaches the critical issue of cleaning massive amounts of radioactive and other contaminated water.
  • Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

General Fusion and Kyoto Fusioneering Sign MOU to Accelerate Commercialization of Magnetized Target Fusion

Retrieved on: 
Wednesday, October 11, 2023

RICHMOND, British Columbia and TOKYO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion and Kyoto Fusioneering announced a Memorandum of Understanding (MOU) to accelerate the commercialization of General Fusion’s proprietary Magnetized Target Fusion (MTF) technology, aiming for grid integration in the early to mid-2030s.

Key Points: 
  • RICHMOND, British Columbia and TOKYO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion and Kyoto Fusioneering announced a Memorandum of Understanding (MOU) to accelerate the commercialization of General Fusion’s proprietary Magnetized Target Fusion (MTF) technology, aiming for grid integration in the early to mid-2030s.
  • Tritium, a hydrogen isotope and key fusion fuel, does not occur naturally and must be produced or “bred” in the fusion process.
  • Kyoto Fusioneering specializes in fusion power plant systems that complement the plasma confinement core, are applicable to various fusion confinement concepts, such as MTF, and are on the critical path for fusion commercialization.
  • “Harnessing the unique technological and engineering expertise of Kyoto Fusioneering will be instrumental as we translate LM26’s groundbreaking results into the world’s first Magnetized Target Fusion power plant.”
    "We're thrilled to join forces with General Fusion.